

Ongoing Clinical Monitoring



Disclosures

Novocure Grant Recipient

Canon Medical Consultant

• Avicenna.ai Shareholder, consultant





Outline







WHY IS IT IMPORTANT?

HOW DO WE GO ABOUT CLINICAL MONITORING?

WHAT ARE TARGETED RESULTS?






Why ?

1. Accountability

- Patients get the right care for their specific situation
- Referrers having their questions / needs met
- Assess impact on our own workflows

2. Early Adopters for this developing technology







Why ?

3. Navigating the hype








Why ?

3. Navigating the noise










While being swamped during weekend call, I had few moments of amusement with epic failures of computer assisted diagnosis! picking up streak artifact for bleed while missing actual hemorrhage; calling ASPECT of 0 in right hemisphere because of large hematoma on the left #AI







Data Input

Pre & Post Processing

Clinical Efficacy
/ Outcome








1. Data Input

- Is data representative of the population the application was trained on?
- Clinical Setting?
- Demographics?
- Disease Prevalence?






How 😲

2. Pre & Post Processing

- Are cases being identified?
- Are cases being appropriate excluded / included
- Are triggers working intended?







What are your targeted clinical results?

- Sensitivity / Specificity?
- Radiology time savings?
 - In what setting?
 - By which group of users?
- Treatment time savings?
- ...Prediction?








Sensitivity / Specificity

- Specificity Ability to correctly classify an individual as disease free
- Sensitivity Ability to correctly classify an individual as diseased

PPV / NPV

- PPV % of patients with a positive test who have disease
- NPV % of patients with a negative test who are disease free









Sensitivity / Specificity

	ICH	No ICH
Test +	900	50
Test -	100	950

Company X trains a new AI to diagnosis ICHs from 2,000 patients with a balanced set of 1000 ICHs and 1000 no ICHs.

• Sen/Spec: 90.0% and 95.0%

PPV / NPV: 94.7% and 90.5%

DATA SCIENCE INSTITUTE® AMERICAN COLLEGE OF RADIOLOGY

Real World PPV / NPV


	ICH	No ICH
Test +	900	1000
Test -	100	19000

Hospital X sees about 20,000 CTs in the ER per year with about 5% positive rate.

• Sen/Spec: 90.0% and 95.0%

PPV / NPV: 47.3% and 99.5%







Real World PPV / NPV

	ICH	No ICH
Test +	900	1000
Test -	100	19000

Company X trains a new AI to diagnosis ICHs from 2,000 patients with a balanced set of 1000 ICHs and 1000 no ICHs.

• Sen/Spec: 90.0% and 95.0%

PPV / NPV: 94.7% and 90.5%

Hospital X sees about 20,000 CTs in the ER per year with about 5% positive rate.

• Sen/Spec: 90.0% and 95.0%

PPV / NPV: 47.3% and 99.5%





Ongoing Clinical Monitoring







WHY IS IT IMPORTANT?

HOW DO WE GO ABOUT CLINICAL MONITORING?

WHAT ARE TARGETED RESULTS?







Thank you

